Literature DB >> 10450746

Effects of TGF-beta on the immune system: implications for cancer immunotherapy.

K E de Visser1, W M Kast.   

Abstract

Transforming growth factor-beta (TGF-beta) is a potent regulator of numerous processes including hematopoiesis, cell proliferation, differentiation and activation. TGF-beta has pleiotropic and profound effects on the immune system and on hematologic malignancies, ie leukemia. It is the most potent immunosuppressor described to date. Evidence exists that the immunosuppressive potential of TGF-beta is an important promoter of malignant cell growth. This is partly caused by TGF-beta-induced interference with the generation of tumor-specific cytotoxic T lymphocytes, but also by TGF-beta-induced promotion of angiogenesis and tumor stroma formation. Until now, significant clinical responses have not been achieved with the current cancer immunotherapeutic approaches. One of the possible explanations for this failure is immunosuppression induced by tumor-derived TGF-beta. Here, several strategies to counteract the immunosuppressive effects of TGF-beta and the current limitations of these strategies will be discussed. Knowledge of the mechanisms by which TGF-beta interferes with the development of an anti-tumor response and of the strategies to counteract these immunosuppressive activities is crucial to improve the current cancer immunotherapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450746     DOI: 10.1038/sj.leu.2401477

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  33 in total

Review 1.  BCG response prediction with cytokine gene variants and bladder cancer: where we are?

Authors:  Dinesh Kumar Ahirwar; Parmeet Kaur Manchanda; Rama Devi Mittal; Hemant K Bid
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-20       Impact factor: 4.553

2.  In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids.

Authors:  R V Goddard; A G Prentice; J A Copplestone; E R Kaminski
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

3.  Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering.

Authors:  Lara Myers; Chikara Takahashi; Robert S Mittler; Robert J Rossi; Anthony T Vella
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-14       Impact factor: 11.205

4.  Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells.

Authors:  Nada Kraguljac Kurtović; Milena Krajnović; Andrija Bogdanović; Nada Suvajdžić; Jelica Jovanović; Bogomir Dimitrijević; Milica Colović; Koviljka Krtolica
Journal:  Med Oncol       Date:  2012-07-07       Impact factor: 3.064

Review 5.  Please stand by: how oncolytic viruses impact bystander cells.

Authors:  Leslee Sprague; Lynne Braidwood; Joe Conner; Kevin A Cassady; Fabian Benencia; Timothy P Cripe
Journal:  Future Virol       Date:  2018-08-08       Impact factor: 1.831

6.  Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.

Authors:  Spencer Ng; Jiusheng Deng; Raghavan Chinnadurai; Shala Yuan; Andrea Pennati; Jacques Galipeau
Journal:  Cancer Res       Date:  2016-08-03       Impact factor: 12.701

7.  TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.

Authors:  Mojgan Ahmadzadeh; Steven A Rosenberg
Journal:  J Immunol       Date:  2005-05-01       Impact factor: 5.422

Review 8.  Rebuilding immunity in cancer patients.

Authors:  Stanimir Vuk-Pavlovic
Journal:  Blood Cells Mol Dis       Date:  2007-09-10       Impact factor: 3.039

9.  Mnk Kinases in Cytokine Signaling and Regulation of Cytokine Responses.

Authors:  Sonali Joshi; Leonidas C Platanias
Journal:  Biomol Concepts       Date:  2012-04

10.  Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment.

Authors:  Joel Fleury Djoba Siawaya; Nchinya Bennedict Bapela; Katharina Ronacher; Nulda Beyers; Paul van Helden; Gerhard Walzl
Journal:  Clin Vaccine Immunol       Date:  2008-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.